F0U Stock Overview

Researches, develops, manufactures, and commercializes nanotechnology products and materials. More details

F0U fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	1/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (1.7x) is below the German market (15.4x)

Became profitable this year

Risk Analysis

Makes less than USD$1m in revenue (CA$0)

Debt is not well covered by operating cash flow

High level of non-cash earnings

Does not have a meaningful market cap (€856K)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

NAVCO Pharmaceuticals Inc. Competitors

Epigenomics

DB:ECX

€971.4k

Restart Life Sciences

CNSX:HEAL

CA$1.3m

2invest

XTRA:2INV

€67.3m

Enzon Pharmaceuticals

OTCPK:ENZN

US$13.9m

Price History & Performance

Summary of share price highs, lows and changes for NAVCO Pharmaceuticals
Historical stock prices
Current Share Price	CA$0.004
52 Week High	CA$0.099
52 Week Low	CA$0.0025
Beta	0
1 Month Change	-73.33%
3 Month Change	-86.67%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-85.29%

Recent updates

Shareholder Returns

	F0U	DE Biotechs	DE Market
7D	0%	-3.5%	-2.0%
1Y	n/a	-14.7%	6.9%

Return vs Industry: Insufficient data to determine how F0U performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how F0U performed against the German Market.

Price Volatility

Is F0U's price volatile compared to industry and market?
F0U volatility
F0U Average Weekly Movement	345.0%
Biotechs Industry Average Movement	6.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: F0U's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: F0U's weekly volatility has increased from 169% to 345% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Geoffrey Lee	navcopharma.com

NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials. It offers aerosol spray, hand cream and sanitizer, and colloidal silver products. The company also provides COVID PCR testing, PPE, and diagnostic PCR testing, as well as textile and food solutions.

NAVCO Pharmaceuticals Inc. Fundamentals Summary

How do NAVCO Pharmaceuticals's earnings and revenue compare to its market cap?
F0U fundamental statistics
Market cap	€570.91k
Earnings (TTM)	€326.34k
Revenue (TTM)	n/a

1.7x

P/E Ratio

0.0x

P/S Ratio

Is F0U overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
F0U income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	-CA$489.32k
Earnings	CA$489.32k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.0086
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	3,488.3%

How did F0U perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 07:47
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NAVCO Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

NAVCO Pharmaceuticals DB:F0U Stock Report